CF AMR Syndicate
Overview
CF AMR Syndicate is a cross-sector initiative managed by Medicines Discovery Catapult, Cystic Fibrosis Trust, and LifeArc that accelerates the development of antimicrobials and diagnostics for cystic fibrosis by providing scientific expertise, resources, and collaborative funding.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Oxford Drug Design | Sep 2024 | Grant | Co-investor |
| Glox Therapeutics | Jan 2025 | Grant | Co-investor |
| Rostra Therapeutics | Nov 2024 | Grant | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is CF AMR Syndicate based?
CF AMR Syndicate is headquartered in United Kingdom.
When was CF AMR Syndicate founded?
CF AMR Syndicate was founded in 2019.
How many portfolio companies does CF AMR Syndicate have?
CF AMR Syndicate has 3 portfolio companies in Caplight's dataset.
What are some companies in CF AMR Syndicate's portfolio?
Portfolio companies visible on Caplight include Oxford Drug Design, Glox Therapeutics, Rostra Therapeutics.
What was CF AMR Syndicate's most recent investment shown here?
CF AMR Syndicate's most recent investment in this portfolio sample was in Glox Therapeutics in 2025.
What sectors does CF AMR Syndicate focus on?
CF AMR Syndicate focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure.
What company stages does CF AMR Syndicate focus on?
Stage focus information for CF AMR Syndicate is not publicly available.